Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

  1. Rugo, H.S.
  2. Ettl, J.
  3. Hurvitz, S.A.
  4. Gonçalves, A.
  5. Lee, K.-H.
  6. Fehrenbacher, L.
  7. Mina, L.A.
  8. Diab, S.
  9. Woodward, N.E.
  10. Yerushalmi, R.
  11. Goodwin, A.
  12. Blum, J.L.
  13. Martin, M.
  14. Quek, R.G.W.
  15. Tudor, I.C.
  16. Bhattacharyya, H.
  17. Gauthier, E.
  18. Litton, J.K.
  19. Eiermann, W.
Revue:
JNCI Cancer Spectrum

ISSN: 2515-5091

Année de publication: 2020

Volumen: 4

Número: 1

Type: Article

DOI: 10.1093/JNCICS/PKZ085 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus